

Hope. Now within reach.

Aiming to reach a billion
patients worldwide with
affordable, lifesaving
medicines



Fact Sheet

Enabling Global Health Equity

As a global frontrunner in the biopharmaceuticals industry, the Biocon Group has dedicated itself to providing high-quality, cost-effective medicines to patients around the world.










Biocon, with its key business verticals of Generics, Biosimilars, and Research Services, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.

Biocon has been significantly impacting patients' health, while creating exponential and enduring value for all its stakeholders for over 45 years.



The Group is guided by a strong sense of purpose to enable health equity worldwide by providing affordable access to essential and lifesaving therapeutics.

Cutting-edge science, large-scale manufacturing capacity and a global commercial footprint allow Biocon to make essential medicines accessible to patients worldwide, at affordable price points. At the same time, the Group entities are efficiently deploying capital and optimizing resources to make an enduring impact on the health of patients, the planet, and the business.


BIOCON GROUP: QUICK FACTS

-  Bengaluru, India  Employees: **18,200+**
-  Commercial reach: **120+ countries**
-  Patents: **1,500+**
-  Biosimilars commercialized globally: **9**
-  Biosimilars in portfolio: **20**
-  APIs in portfolio: **60+**
-  Generic Formulations in portfolio: **75+**
-  Syngene's client base: **400+**

FY2025 - FINANCIAL HIGHLIGHTS

-  Annual revenue: **₹164,699 mn (\$1.95 bn)**
-  EBITDA: **₹43,745 mn**
-  EBITDA margin: **27%**
-  Annual profit: **₹10,133 mn**
-  Gross R&D spend: **₹8,585 mn**

FY2025 - REVENUE BREAK-UP



Our Vision

- To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners, and healthcare systems across the globe.

Our Values

- Value creation through innovation and differentiation.
- Quality through compliance and best practices.
- Integrity and ethical behavior.
- Collaboration, teamwork and mutual respect.
- Performance-driven work culture.

BIOCON IS DELIVERING ON ITS VISION THROUGH ITS THREE PRINCIPAL BUSINESSES.

Generics Business

Ensuring Access through Quality, Affordability, Reliability

The Group's Generics vertical, managed by **Biocon Limited**, is dedicated to manufacturing and supplying affordable generic bulk drugs and finished formulations. The Generics business comprises a growing portfolio of Active Pharmaceutical Ingredients (APIs) as well as finished dosages.

Biocon is the leading global manufacturer of statin and immunosuppressant APIs. Biocon forayed into generic formulations in 2013, with a strategy to forward integrate its in-house, complex and differentiated APIs and move up the value chain, ensuring reliability of quality and supply to its customers and patients.

The APIs pipeline includes 60+ products, spanning cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules which has been further augmented to include oncology-based Highly Potent APIs (HPAPIs) and peptides, particularly Glucagon-like peptide-1 receptor agonists (GLP-1s), that address diabetes and weight management. Biocon serves 750+ pharma companies across 100+ countries.

The Generics business launched generic Liraglutide for diabetes and obesity in the U.K. in February 2025 following approval from MHRA, UK, in March 2024, making Biocon Limited the first generics company to obtain approval for generic Liraglutide in a major regulated market.

The Generic Formulations portfolio comprises 75+ products across cardiology, oncology, immunology, and autoimmune indications. The company has a long and proud history of maintaining high standards of quality and compliance, having received 90+ cGMP approvals from international regulatory bodies.

Biocon's global commercial strategy combines direct selling, licensing, and partnerships for market expansion.



Biosimilars Business

Transforming Healthcare. Transforming Lives.

Biocon Biologics Limited is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company specializes in developing, manufacturing, and commercializing a differentiated and comprehensive biosimilars portfolio including insulins, monoclonal antibodies and conjugated recombinant proteins.

Biocon Biologics has commercialized nine biosimilars from its portfolio which are addressing the patients' needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. The Company has a portfolio of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. Biocon Biologics has established its credibility as a leading biosimilars player with a proven track record of scientific excellence by achieving many 'firsts' in the industry.

The Company ranks among the world's Top 15 biomanufacturing companies in terms of capacity and is among the leading insulin producers worldwide. Adherence to the highest quality standards for biosimilars has led Biocon Biologics to obtain 90+ cGMP approvals from international regulatory agencies.

Biocon Biologics has a commercial presence in 120+ countries through self-led, partner-led and hybrid business models. The Company has customer-facing commercial capabilities and related infrastructure in several markets worldwide such as the U.S., Canada, and 19 European countries, including the Top 5 markets of UK, Germany, France, Spain and Italy. It has commercial reach across 80+ Emerging Market countries, of which there is a direct commercial presence in 8 countries.



Research Services Business

Putting Science to Work

Syngene International Limited is an integrated research, development, and manufacturing services company catering to various sectors such as pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals.

Syngene's team of over 5,600 scientists possesses the expertise and capability to deliver great science, ensuring robust data security and high-quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb, along with 2.5 million square feet of specialist discovery, development, and manufacturing facilities, Syngene collaborates with biotech companies and multinationals like GSK, Zoetis, BMS and Merck KGaA, supporting their pursuit of leading-edge science.



Strong ESG Focus

Biocon's corporate culture is anchored in purpose, ethics, and equity. From addressing health disparities to promoting community well-being and environmental stewardship, Biocon's Environmental, Social and Governance (ESG) strategy is aimed at shaping a future where business success and responsibility intertwines with societal progress.

The Group's strategy, which encompasses globally benchmarked policies, processes, and practices, ensures that purpose-inspired responsible business principles and the highest standards of ethics and governance guide its actions. It has integrated responsible business principles not only within the Company but also throughout its value chain. Biocon's approach, rooted in good governance, transparency, and accountability underscores its commitment to long-term sustainable value creation.

Biocon Limited has set itself ambitious targets for reducing its Scope 1 and Scope 2 emissions, lowering freshwater consumption, and ensuring 100% recycling of waste.

Biocon improved its Global ESG Score by 6 points to 69 in the 2024 S&P Corporate Sustainability Assessment. The Company's inclusion in the S&P Global Sustainability Yearbook 2025 for the third consecutive year is testament to its unwavering commitment to integrate ESG principles in its business purpose and practices.



Biocon Foundation, the Corporate Social Responsibility (CSR) arm of Biocon Group, has been working in the areas of socio-economic upliftment through programs aimed at improving healthcare access, education opportunities, environmental sustainability, rural and urban civic infrastructure since 2005. The Foundation's comprehensive programs address the myriad developmental challenges facing India by delivering scalable solutions through innovative and sustainable models.

The Foundation has developed and nurtured strong relationships with the local community and other stakeholders. It has also nurtured long-term strategic partnerships with tertiary healthcare providers to get technical support and with governments to fulfil mutual obligations in a public-private partnership (PPP) mode.

The Biocon Academy, founded in 2013, spearheads the Biocon Group's CSR initiatives in technical and professional education for aspiring biotechnologists. The Academy imparts rigorous academic learning and world-class industry-oriented training programs on applied aspects of various life sciences disciplines. In doing so, the Academy is helping create an enabling environment that molds everyone into highly capable, forward-looking self-starters, equipped with the skills, experience and knowledge to move India forward.





KEY AWARDS AND RECOGNITIONS



Biocon Group

- Ranked no. 9 among Top 10 Employers globally by U.S.-based Science magazine.
- Recognized as 'Sunrise Sector Pioneer' for the largest investment in Biotechnology and Life Sciences manufacturing at 'Invest Karnataka 2025'.
- Won Gold Medal for Best Health CSR Campaign for 'Oral Cancer Care Programme' at PRmoment India Health Comms Award 2024.

Biocon Limited

- Scored 'A' in CDP Supplier Engagement Rating, placing Biocon in Leadership band, surpassing Asia regional average of 'C' and Biotech & Pharm average of 'B'.
- Won 'Excellence in Sustainability Award' at Indian Pharma Awards by CPHI India 2024.
- Placed in 'Top 5' Pharma & Healthcare Most Sustainable Companies at BW Businessworld Sustainability Awards 2024.
- Received the Best Organizations for Women Award 2025 by ET NOW.
- Won National EHS Award 'Large Enterprises' (Pharmaceuticals Sector) for innovation in ESG strategies at 12th Global Safety Summit.

Biocon Biologics

- Won the "High Yield Bond of the Year" Award from the prestigious IFR Asia.
- Recognized for 'Bioprocessing Excellence in South Asia' at Asia-Pacific Biopharma Excellence Awards 2024.
- Won Best Patent Award 2021-2024 from Indian Drug Manufacturers' Association.
- Received National Intellectual Property Award 2024 as 'Top Indian Company for creating Brand in India and Abroad' from Intellectual Property Office, India.
- Won '2024 Best Companies for Women in India' for 8th time by Avtar.
- Won 'Compliance Team of the Year Award' at 4th Edition of Future of Legal and Compliance Summit by UBS Forums.

Syngene

- Won Silver rating from EcoVadis, placing Syngene in top 15% of all companies assessed globally for sustainability.
- Ranked No. 1 pharma company with most women employees in Fortune India Top 10 list.
- Achieved 5S Certification from JUSE and QCFI as 1st in Pharma and Life Sciences industry.
- Ranked 9th in pharmaceutical sector and only CRDMO in 'Business World India's Most Sustainable Companies' list.

Biocon Foundation

- Won 'Doing Good for Bharat Awards' 2024 in healthcare category for flagship 'eLAJ Smart Clinics' for serving underserved communities at 11th India CSR & ESG Summit by CSRBOX.
- Honoured at 2nd 'Arogya City Summit 2024 – Making Bengaluru A Healthier City' for contributing to public health.

Note: The information in this Fact Sheet is given as of the date mentioned, and Biocon does not assume any obligation to update the information on a frequent basis.

Last Updated: May 2025

Biocon Group Key Management Team



Kiran Mazumdar-Shaw
Chairperson, Biocon Group



Siddharth Mittal
CEO & Managing Director
Biocon Limited



Shreehas Tambe
CEO & Managing Director
Biocon Biologics Limited



Peter Bains
CEO & Managing Director
Syngene International Limited

Biocon Limited

20th KM, Hosur Road, Electronic City,
Bengaluru, India 560 100

For more information:

Seema Ahuja,
SVP & Global Head of Communications
& Corporate Brands, Biocon Group
Email: Group.Communications@biocon.com

Website: www.biocon.com
Email: info@biocon.com
Twitter: @Bioconlimited
LinkedIn: /company/biocon/
Facebook: @Bioconlimited

Follow us at : 